Sellas Life Sciences Group (ehemals Galena Biopharma) - Älteste Beiträge zuerst (Seite 88)
eröffnet am 30.10.12 22:43:19 von
neuester Beitrag 19.01.24 22:21:17 von
neuester Beitrag 19.01.24 22:21:17 von
Beiträge: 2.935
ID: 1.177.530
ID: 1.177.530
Aufrufe heute: 0
Gesamt: 345.721
Gesamt: 345.721
Aktive User: 0
ISIN: US81642T2096 · WKN: A2PU3T · Symbol: SLS
1,5200
USD
+7,80 %
+0,1100 USD
Letzter Kurs 02:00:00 Nasdaq
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 3,5800 | +922,86 | |
| 1,0400 | +48,57 | |
| 0,5400 | +38,46 | |
| 5,4000 | +27,06 | |
| 1,9900 | +26,75 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 5,3700 | -25,93 | |
| 3,0200 | -27,58 | |
| 28,18 | -32,62 | |
| 3,6400 | -38,62 | |
| 0,5660 | -40,42 |
Feedback
Antwort auf Beitrag Nr.: 49.452.101 von Schaeffi am 30.03.15 08:29:37Hi Schaeffi, ich warte nicht mehr...
habe meine Postion vorhin 'brav' nach oben "abgerundet"
(hier kauft man am tief des sechsmonats verlauf bei bester Aussichten, bald gibts gar kein Grund mehr zum shorten)
und ja, Du hast selbsverständlich Recht, Pharmacyclics war gemeint, werde nur die jeweilige kürzel (PCYC) benutzen ab jetzt
habe meine Postion vorhin 'brav' nach oben "abgerundet"
(hier kauft man am tief des sechsmonats verlauf bei bester Aussichten, bald gibts gar kein Grund mehr zum shorten) und ja, Du hast selbsverständlich Recht, Pharmacyclics war gemeint, werde nur die jeweilige kürzel (PCYC) benutzen ab jetzt
Very interesting article re Dr. Elizabeth Mittendorp (etwas Ernst die Dame, aber dafür die letzte Instanz im sachen Breast Cancer Research, inkl. Neuvax's mögliche Anwendungsgebiet(e)...
Hope Rises for Immunotherapy in Breast Cancer
http://www.onclive.com/web-exclusives/Hope-Rises-for-Immunot…
...hope rises indeed
(1,40$ zurzeit and counting)
Hope Rises for Immunotherapy in Breast Cancer
http://www.onclive.com/web-exclusives/Hope-Rises-for-Immunot…
...hope rises indeed
(1,40$ zurzeit and counting)
Antwort auf Beitrag Nr.: 49.459.958 von Growth2012 am 30.03.15 23:02:24and I quote...
In a phase I/II trial as adjuvant therapy on 187 women with node-positive and high-risk node-negative tumors that expressed any degree of HER2, the 5-year rate of disease-free survival (DFS) was 89.7% overall for those who received the vaccine compared with 80.2% for unvaccinated women.1 For optimally dosed patients, the DFS rate rose to 94.6%.
In a phase I/II trial as adjuvant therapy on 187 women with node-positive and high-risk node-negative tumors that expressed any degree of HER2, the 5-year rate of disease-free survival (DFS) was 89.7% overall for those who received the vaccine compared with 80.2% for unvaccinated women.1 For optimally dosed patients, the DFS rate rose to 94.6%.
Antwort auf Beitrag Nr.: 49.459.958 von Growth2012 am 30.03.15 23:02:24Growth schöner Artikel
hier was mir daraus augen
fällig wurde:
Immunotherapy development currently tends to focus broadly on three treatment categories: chimeric antigen receptor (Car) T-cell therapies, vaccines, and checkpoint blockade strategies. Car therapies, which coat the patient’s T cells to help those cells recognize tumor antigens, remain largely untested against breast cancer, so Mittendorf focused on vaccines and checkpoint inhibitors.
bei CART Technologie soll MGNX stark sein
Vaccine Leads Field
For patients with breast cancer, the most advanced vaccine is nelipepimut-S (neuvax). The formulation is a peptide derived from HER2 protein, combined with the immunoadjuvant granulocyte-macrophage colony-stimulating factor (GM-CSF). Patients receive it monthly for 6 months and then every 6 months thereafter for up to 3 years.
In a phase I/II trial as adjuvant therapy on 187 women with node-positive and high-risk node-negative tumors that expressed any degree of HER2, the 5-year rate of disease-free survival (DFS) was 89.7% overall for those who received the vaccine compared with 80.2% for unvaccinated women.1 For optimally dosed patients, the DFS rate rose to 94.6%.
The phase III PRESENT trial now under way seeks to randomize 700 women with early-stage, node-positive breast cancer with low to intermediate HER2 expression (HER2 1+ by IHC or HER2 2+ by IHC/FISH) to NeuVax or an active comparator composed of the GM-CSF sargramostim (Leukine).2 To be eligible for the trial, patients must have primary tumor stage T1-3 at initial diagnosis that was completely excised through surgery or are receiving neoadjuvant therapy before surgery.
mit Spannung erwartet
“Vaccination takes months to produce an immune response, so it’s probably not an appropriate treatment strategy for very late-stage cancers, but it appears to be particularly appropriate in an adjuvant setting,” said Mittendorf, who has been leading the nelipepimut-S trials.
Impfungen sind im akuten Stadium weniger wirksam, frühzeitige Behandlung wichtig (ähnlich Grippe Impfung)
“At that point, when most patients are already disease-free, harsh treatments make no sense. The tradeoff between toxicity and benefit is not in the patient’s favor. Effective vaccines, on the other hand, make perfect sense because they rarely subject patients to anything worse than mild pain or itching at the injection site. NeuVax is no more grueling than a flu shot.”
Nebewirkungen wie ne Grippeimpfung
There is also reason to think that many vaccines will prove more effective in the adjuvant setting than they have, to date, in the advanced-disease setting. Vaccines against infectious diseases rank among the most beneficial tools created by medical science, but they have a major limitation. They’re far better at prevention than treatment. In general, the more a patient already suffers from the target disease at the time of vaccination, the less a vaccine helps the patient.
“We don’t know enough yet to make blanket statements about the optimal timing for different immunotherapies, but anecdotal evidence suggests that vaccines are less effective in patients with advanced metastatic cancer,” Mittendorf said. “It would explain why many of the earliest vaccine trials, which enrolled patients with diffusely metastatic tumors, failed to demonstrate benefit.
“Timing, in general, is critical in oncology, and it may prove particularly important with immunotherapy,” she said. “Research needs to demonstrate not only whether treatments work but when and how they work the best so that clinicians can prescribe each patient the right treatment at the right time.” - See more at: http://www.onclive.com/web-exclusives/Hope-Rises-for-Immunot…
Timing ist sehr wichtig
Gruss S.
hier was mir daraus augen
fällig wurde:Immunotherapy development currently tends to focus broadly on three treatment categories: chimeric antigen receptor (Car) T-cell therapies, vaccines, and checkpoint blockade strategies. Car therapies, which coat the patient’s T cells to help those cells recognize tumor antigens, remain largely untested against breast cancer, so Mittendorf focused on vaccines and checkpoint inhibitors.
bei CART Technologie soll MGNX stark sein
Vaccine Leads Field
For patients with breast cancer, the most advanced vaccine is nelipepimut-S (neuvax). The formulation is a peptide derived from HER2 protein, combined with the immunoadjuvant granulocyte-macrophage colony-stimulating factor (GM-CSF). Patients receive it monthly for 6 months and then every 6 months thereafter for up to 3 years.
In a phase I/II trial as adjuvant therapy on 187 women with node-positive and high-risk node-negative tumors that expressed any degree of HER2, the 5-year rate of disease-free survival (DFS) was 89.7% overall for those who received the vaccine compared with 80.2% for unvaccinated women.1 For optimally dosed patients, the DFS rate rose to 94.6%.
The phase III PRESENT trial now under way seeks to randomize 700 women with early-stage, node-positive breast cancer with low to intermediate HER2 expression (HER2 1+ by IHC or HER2 2+ by IHC/FISH) to NeuVax or an active comparator composed of the GM-CSF sargramostim (Leukine).2 To be eligible for the trial, patients must have primary tumor stage T1-3 at initial diagnosis that was completely excised through surgery or are receiving neoadjuvant therapy before surgery.
mit Spannung erwartet
“Vaccination takes months to produce an immune response, so it’s probably not an appropriate treatment strategy for very late-stage cancers, but it appears to be particularly appropriate in an adjuvant setting,” said Mittendorf, who has been leading the nelipepimut-S trials.
Impfungen sind im akuten Stadium weniger wirksam, frühzeitige Behandlung wichtig (ähnlich Grippe Impfung)
“At that point, when most patients are already disease-free, harsh treatments make no sense. The tradeoff between toxicity and benefit is not in the patient’s favor. Effective vaccines, on the other hand, make perfect sense because they rarely subject patients to anything worse than mild pain or itching at the injection site. NeuVax is no more grueling than a flu shot.”
Nebewirkungen wie ne Grippeimpfung
There is also reason to think that many vaccines will prove more effective in the adjuvant setting than they have, to date, in the advanced-disease setting. Vaccines against infectious diseases rank among the most beneficial tools created by medical science, but they have a major limitation. They’re far better at prevention than treatment. In general, the more a patient already suffers from the target disease at the time of vaccination, the less a vaccine helps the patient.
“We don’t know enough yet to make blanket statements about the optimal timing for different immunotherapies, but anecdotal evidence suggests that vaccines are less effective in patients with advanced metastatic cancer,” Mittendorf said. “It would explain why many of the earliest vaccine trials, which enrolled patients with diffusely metastatic tumors, failed to demonstrate benefit.
“Timing, in general, is critical in oncology, and it may prove particularly important with immunotherapy,” she said. “Research needs to demonstrate not only whether treatments work but when and how they work the best so that clinicians can prescribe each patient the right treatment at the right time.” - See more at: http://www.onclive.com/web-exclusives/Hope-Rises-for-Immunot…
Timing ist sehr wichtig
Gruss S.
Galena Biopharma to Present at the 14th Annual Needham Healthcare Conference (Am 14.04 in The Westin H. in New York City)
http://finance.yahoo.com/news/galena-biopharma-present-14th-…
http://finance.yahoo.com/news/galena-biopharma-present-14th-…
Trading Spotlight
Antwort auf Beitrag Nr.: 49.465.922 von Growth2012 am 31.03.15 15:59:52Insider kaufen...
Antwort auf Beitrag Nr.: 49.460.948 von Schaeffi am 31.03.15 08:40:35
da is mir wohl ein Fehler unterlaufen
CART = JUNO
MGNX = Dual-Affinity Re-Targeting (DART)
Zitat von Schaeffi: Growth schöner Artikel
Immunotherapy development currently tends to focus broadly on three treatment categories: chimeric antigen receptor (Car) T-cell therapies, vaccines, and checkpoint blockade strategies. Car therapies, which coat the patient’s T cells to help those cells recognize tumor antigens, remain largely untested against breast cancer, so Mittendorf focused on vaccines and checkpoint inhibitors.
bei CART Technologie soll MGNX stark sein
da is mir wohl ein Fehler unterlaufen
CART = JUNO
MGNX = Dual-Affinity Re-Targeting (DART)
Gale Expands Patient Population in NeuVax(TM)
http://finance.yahoo.com/news/galena-biopharma-expands-patie…
http://finance.yahoo.com/news/galena-biopharma-expands-patie…
Money1469 (der wohl sehr gut informiert ist) hat's die Tage drüben auf Yahoo auf dem Punkt gebracht, das Posting könnte ich mehrmals am Tag durchlesen wegen der klare Gedankenstruktur (nichtmal Schwartz's manachmal schlechte Führungsstil könnte die positve Ausgangslage -sprich GALE's Ausgangslage April 15- komplett wiederlegen)
Why I hold GALE and continue to accumulate Share-- at requests of Jim
As each day goes, and no negative news flow from validated sources about Gale's multiple trials the probability increases of a successful outcome. NeuVax would be the second vaccine to receive FDA approval in relation to cancer, most approvals deal with antibody, DNDN vaccine (provenge) was the first but lacked convenience to patients and it was too costly as well as significant side effects. NeuVax has:
1. Costs of production low
2. Patience convenience (big one)
3. Minimum side effects, just reddish to skin
4. Limited number of doctor's visits (11 times within 3yr period)
5. 3-years benefit to DFS (which will validated in this coming Dec/Jan)
6. NeuVax can work or will work within multiple cancer types in preventative fashion after standard care
Now the Company Gale:
1. Gale has reconfigured it's management team with industry vets, CEO owns 415,000 shares +++warrants
2. Gale has obtained funding for all programs with partnerships with Roche, DOD, Dr. Redd
3. Gale has funding to support operations well into 2017
4. Most importantly, the Science is Sound and has never been challenged on validity
5. Blackrock significantly increased holding of Gale within the last 60 days
6. Abstrals revenues are increasing each quarter and is second in the market in EU- producing revenues 30-60 Million in the EU. Gale projection of 15-18 million is very conservative.
For all of the above reasons, I continue to hold and accumulate shares. This is the forum in which I share my research, knowledge and excitement in hopes it will benefit others as well as myself. Always do your own DD, and remember FUD is a factor.
http://finance.yahoo.com/mbview/threadview/?&bn=12a6b315-348…
Why I hold GALE and continue to accumulate Share-- at requests of Jim
As each day goes, and no negative news flow from validated sources about Gale's multiple trials the probability increases of a successful outcome. NeuVax would be the second vaccine to receive FDA approval in relation to cancer, most approvals deal with antibody, DNDN vaccine (provenge) was the first but lacked convenience to patients and it was too costly as well as significant side effects. NeuVax has:
1. Costs of production low
2. Patience convenience (big one)
3. Minimum side effects, just reddish to skin
4. Limited number of doctor's visits (11 times within 3yr period)
5. 3-years benefit to DFS (which will validated in this coming Dec/Jan)
6. NeuVax can work or will work within multiple cancer types in preventative fashion after standard care
Now the Company Gale:
1. Gale has reconfigured it's management team with industry vets, CEO owns 415,000 shares +++warrants
2. Gale has obtained funding for all programs with partnerships with Roche, DOD, Dr. Redd
3. Gale has funding to support operations well into 2017
4. Most importantly, the Science is Sound and has never been challenged on validity
5. Blackrock significantly increased holding of Gale within the last 60 days
6. Abstrals revenues are increasing each quarter and is second in the market in EU- producing revenues 30-60 Million in the EU. Gale projection of 15-18 million is very conservative.
For all of the above reasons, I continue to hold and accumulate shares. This is the forum in which I share my research, knowledge and excitement in hopes it will benefit others as well as myself. Always do your own DD, and remember FUD is a factor.
http://finance.yahoo.com/mbview/threadview/?&bn=12a6b315-348…
Unfassbar:- der Autor "Sean Williams", wird offensichtlich Bezahlt vom interessiert dritte um glassklar 'Positives in Negatives' zu verwandeln, bitte ganz genau durchlesen -(mit GALE's positive Aussichten wird versucht -eher amateurhaft- alles negativ erscheinen zu lassen) bzw. durch dem Kakao gezogen.
4 Ways Galena Biopharma Could Disappoint Investors
http://www.investopedia.com/stock-analysis/033115/4-ways-gal…
Gerade diese extrem "durchsichtigen Vorhaben" des schreibers, stärk mein Überzeugung bzgl. Gales Werthaltigkeit/drastische Unterbewertung zurzeit
4 Ways Galena Biopharma Could Disappoint Investors
http://www.investopedia.com/stock-analysis/033115/4-ways-gal…
Gerade diese extrem "durchsichtigen Vorhaben" des schreibers, stärk mein Überzeugung bzgl. Gales Werthaltigkeit/drastische Unterbewertung zurzeit
DurchsuchenBeitrag zu dieser Diskussion schreiben
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| 0,00 | |
| -2,55 | |
| -0,73 | |
| 0,00 | |
| +0,60 | |
| -6,93 | |
| +1,22 | |
| 0,00 | |
| -1,34 | |
| +1,74 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 179 | ||
| 120 | ||
| 77 | ||
| 58 | ||
| 57 | ||
| 57 | ||
| 55 | ||
| 51 | ||
| 44 | ||
| 40 |
